Has apotex's ruxolitinib us application been approved?

Has Apotex filed a US application for ruxolitinib?

Apotex submitted an ANDA for a generic version of ruxolitinib to the FDA in 2022. The status of that application remains under review.

What is Apotex trying to do with ruxolitinib?

Ruxolitinib is the active ingredient in Jakafi, a JAK inhibitor used to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Apotex aims to launch a generic competitor once patent protection falls away.

When does the Jakafi patent expire?

The primary US compound patent for ruxolitinib expires in 2026. Additional method-of-use and formulation patents extend exclusivity through 2030. [1]

Why are companies challenging this patent?

Multiple generic firms, including Apotex, have filed paragraph IV challenges against the Jakafi patents. These challenges seek to invalidate or design around the patents to gain early market entry.

Can biosimilars enter before patent expiry?

Ruxolitinib is a small-molecule drug, not a biologic. No biosimilar pathway exists for it. Generic versions require successful ANDA approval and patent resolution.

What side effects are patients asking about?

Patients show concern over ruxolitinib's risk of infection, cytopenias, and nonmelanoma skin cancers. Generic entrants like Apotex's product will carry the same labeling and risks.

Who makes the original drug?

Incyte developed ruxolitinib and markets it as Jakafi. Apotex is one of several generic companies pursuing a US launch.